201 related articles for article (PubMed ID: 31646743)
1. Psoriasis Associated With Tumor Necrosis Factor Inhibitors in Children With Inflammatory Diseases.
Buckley LH; Xiao R; Perman MJ; Grossman AB; Weiss PF
Arthritis Care Res (Hoboken); 2021 Feb; 73(2):215-220. PubMed ID: 31646743
[TBL] [Abstract][Full Text] [Related]
2. Incidence Rates of Psoriasis in Children With Inflammatory Bowel Disease and Juvenile Arthritis Treated With Tumor Necrosis Factor Inhibitors and Disease-Modifying Antirheumatic Drugs.
Baggett K; Brandon TG; Xiao R; Valenzuela Z; Buckley LH; Weiss PF
J Rheumatol; 2022 Aug; 49(8):935-941. PubMed ID: 35428721
[TBL] [Abstract][Full Text] [Related]
3. Paradoxical Psoriasis in Children Receiving Anti-TNFα Treatment for Inflammatory/autoimmune Disease.
Rosenwasser N; Lee D; Sidbury R; Zhao Y
Paediatr Drugs; 2021 Mar; 23(2):131-141. PubMed ID: 33761130
[TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor-α inhibitor-induced psoriasis in juvenile idiopathic arthritis patients.
Groth D; Perez M; Treat JR; Castelo-Soccio L; Nativ S; Weiss PF; Lapidus S; Perman MJ
Pediatr Dermatol; 2019 Sep; 36(5):613-617. PubMed ID: 31240749
[TBL] [Abstract][Full Text] [Related]
5. Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors.
Beukelman T; Xie F; Chen L; Horton DB; Lewis JD; Mamtani R; Mannion MM; Saag KG; Curtis JR
Ann Rheum Dis; 2018 Jul; 77(7):1012-1016. PubMed ID: 29440001
[TBL] [Abstract][Full Text] [Related]
6. Absolute and Relative Risk of New-Onset Psoriasis Associated With Tumor Necrosis Factor-α Inhibitor Treatment in Patients With Immune-Mediated Inflammatory Diseases: A Danish Nationwide Cohort Study.
Thein D; Egeberg A; Skov L; Loft N
JAMA Dermatol; 2022 Sep; 158(9):997-1004. PubMed ID: 35767240
[TBL] [Abstract][Full Text] [Related]
7. Psoriasis rate is increased by the exposure to TNF inhibition in children with JIA.
Zhao Y; Sullivan E; Son MB; Beukelman T
Ann Rheum Dis; 2022 May; 81(5):662-665. PubMed ID: 35086815
[TBL] [Abstract][Full Text] [Related]
8. Incident psoriasis under treatment with tumor necrosis factor-α inhibitors in juvenile idiopathic arthritis patients-analysis of the BiKeR registry.
Zimmer A; Klein A; Kuemmerle-Deschner JB; Dressler F; Onken N; Brueck N; Fasshauer M; Hospach T; Hufnagel M; Foell D; Horneff G
Rheumatol Int; 2023 Sep; 43(9):1675-1684. PubMed ID: 37291093
[TBL] [Abstract][Full Text] [Related]
9. Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders?
Chen Y; Friedman M; Liu G; Deodhar A; Chu CQ
Cytokine; 2018 Jan; 101():78-88. PubMed ID: 27688201
[TBL] [Abstract][Full Text] [Related]
10. Use of Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Juvenile Idiopathic Arthritis or Rheumatoid Arthritis.
Lee WJ; Briars L; Lee TA; Calip GS; Suda KJ; Schumock GT
Pharmacotherapy; 2016 Dec; 36(12):1201-1209. PubMed ID: 27779782
[TBL] [Abstract][Full Text] [Related]
11. TNF-α inhibitor-induced psoriasis: A decade of experience at the Cleveland Clinic.
Mazloom SE; Yan D; Hu JZ; Ya J; Husni ME; Warren CB; Fernandez AP
J Am Acad Dermatol; 2020 Dec; 83(6):1590-1598. PubMed ID: 30576759
[TBL] [Abstract][Full Text] [Related]
12. Risk of serious bacterial infection associated with tumour necrosis factor-alpha inhibitors in children with juvenile idiopathic arthritis.
Lee WJ; Lee TA; Suda KJ; Calip GS; Briars L; Schumock GT
Rheumatology (Oxford); 2018 Feb; 57(2):273-282. PubMed ID: 28431162
[TBL] [Abstract][Full Text] [Related]
13. Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis.
Derakhshan MH; Dean L; Jones GT; Siebert S; Gaffney K
RMD Open; 2020 Jul; 6(2):. PubMed ID: 32641447
[TBL] [Abstract][Full Text] [Related]
14. Timing of infliximab and adalimumab initiation despite methotrexate in children with chronic non-infectious anterior uveitis.
McCracken C; Yeh S; Jenkins K; Travers C; Stryker D; Tommasello S; Rouster-Stevens KA; Lambert SR; Prahalad S; Drews-Botsch C; Angeles-Han ST
Eye (Lond); 2019 Apr; 33(4):629-639. PubMed ID: 30487588
[TBL] [Abstract][Full Text] [Related]
15. Risk of Serious Bacterial Infection Associated With Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Inflammatory Bowel Disease.
Lee WJ; Lee TA; Calip GS; Suda KJ; Briars L; Schumock GT
Inflamm Bowel Dis; 2018 Mar; 24(4):883-891. PubMed ID: 29562275
[TBL] [Abstract][Full Text] [Related]
16. Serious Adverse Events Associated with Anti-Tumor Necrosis Factor Alpha Agents in Pediatric-Onset Inflammatory Bowel Disease and Juvenile Idiopathic Arthritis in A Real-Life Setting.
Pastore S; Naviglio S; Canuto A; Lepore L; Martelossi S; Ventura A; Taddio A
Paediatr Drugs; 2018 Apr; 20(2):165-171. PubMed ID: 29214394
[TBL] [Abstract][Full Text] [Related]
17. Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis.
Lee MP; Desai RJ; Jin Y; Brill G; Ogdie A; Kim SC
JAMA Dermatol; 2019 Jun; 155(6):700-707. PubMed ID: 30916734
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with reduced infliximab exposure in the treatment of pediatric autoimmune disorders: a cross-sectional prospective convenience sampling study.
Funk RS; Shakhnovich V; Cho YK; Polireddy K; Jausurawong T; Gress K; Becker ML
Pediatr Rheumatol Online J; 2021 May; 19(1):62. PubMed ID: 33933127
[TBL] [Abstract][Full Text] [Related]
19. Comparison of infection-related hospitalization risk and costs in tumor necrosis factor inhibitor-experienced patients with rheumatoid arthritis (RA) treated with abatacept or other targeted disease-modifying anti-rheumatic drugs (tDMARDs).
Paul D; Patil D; McDonald L; Patel V; Lobo F
J Med Econ; 2020 Sep; 23(9):1025-1031. PubMed ID: 32427547
[No Abstract] [Full Text] [Related]
20. TNF Inhibitors and Risk of Malignancy in Patients with Inflammatory Bowel Diseases: A Systematic Review.
Muller M; D'Amico F; Bonovas S; Danese S; Peyrin-Biroulet L
J Crohns Colitis; 2021 May; 15(5):840-859. PubMed ID: 32915970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
